![]() We have received 39 reports of suspected myocarditis and/or pericarditis in this age group. The most common reactions reported included chest pain, vomiting, fever, headache and abdominal pain. ![]() To 16 October 2022, we have received about 1,640 reports from approximately 2.3 million Comirnaty (Pfizer) and Spikevax (Moderna) doses administered in this age group. The TGA is also closely monitoring adverse event reports in 5-11 year olds. The most commonly reported reactions are chest pain, headache, dizziness, nausea and fever. To 16 October 2022, we have received about 4,280 reports from approximately 3.7 million doses of Comirnaty (Pfizer) and Spikevax (Moderna) in 12-17 year olds. The rate of reports has stabilised with only a small number now being received each week. The TGA is closely monitoring adverse event reports in people aged under 18 years. The most up-to-date vaccine recommendations for children are available from the Australian Technical Advisory Group on Immunisation (ATAGI). Vaccine safety in children and adolescents More information about what to expect and how to manage any symptoms after you receive your vaccine are available from NPS MedicineWise. These are recognised side effects of vaccination and are usually transient and mild. Skin reactions at the site of the injection are also common and can include pain, swelling, redness and an itchy rash. The most frequently reported side effects suspected to be associated with the vaccines include headache, muscle and joint pain, fever, chills and nausea. Learn more about how to report a suspected side effect to a COVID-19 vaccine. by calling the NPS MedicineWise Adverse Medicine Events phone line for consumers.Learn more about how the TGA identifies and responds to safety issues.Īnyone can report a suspected side effect, either: The risk of TTS is much lower after the second dose (0.3 in every 100,000 vaccinated people). Our analysis shows it is reported in about 2 in every 100,000 vaccinated people following the first dose. Thrombosis with thrombocytopenia syndrome (or TTS) is a very rare but serious side effect of Vaxzevria (AstraZeneca).To 16 October 2022, the TGA has received 705 reports which have been assessed as likely to be myocarditis from about 44.2 million doses of Comirnaty (Pfizer) and 115 reports which have been assessed as likely to be myocarditis from about 5.4 million doses of Spikevax (Moderna).It occurs in males and females but is more common after the second dose in boys aged 12-17 years (13 cases per 100,000 Comirnaty doses and 24 cases per 100,000 Spikevax doses) and men under 30 (9 cases per 100,000 Comirnaty doses and 23 cases per 100,000 Spikevax doses). Myocarditis is reported in around 1-2 in every 100,000 people who receive Comirnaty (Pfizer) and around 2 in every 100,000 of those who receive Spikevax (Moderna). ![]() ![]() It is usually temporary, with most people getting better within a few days. Myocarditis is a known but very rare side effect of Comirnaty (Pfizer) and Spikevax (Moderna).thrombosis with thrombocytopenia syndrome (TTS), Guillain-Barre syndrome (GBS) and immune thrombocytopenia (ITP) following Vaxzevria (AstraZeneca) in adults.myocarditis and pericarditis (inflammation of the heart or membrane around the heart) following vaccination, particularly in younger age groups.We are carefully monitoring and reviewing reports of:.This reflects what was seen in the clinical trials. The most frequently reported include injection-site reactions (such as a sore arm) and more general symptoms, like headache, muscle pain, fever and chills. Like all medicines, COVID-19 vaccines may cause some side effects.The most up-to-date recommendations for the use of the COVID-19 vaccines are available from the Australian Technical Advisory Group on Immunisation (ATAGI).The protective benefits of vaccination far outweigh the potential risks. Vaccination against COVID-19 is the most effective way to reduce deaths and severe illness from infection.Learn more about causality and our COVID-19 vaccine safety monitoring and reporting activities. We encourage people to report suspected side effects, even if there's only a very small chance a vaccine was the cause. This is the most intensive safety monitoring ever conducted of any vaccines in Australia. The TGA closely monitors reports of suspected side effects (also known as adverse events) to the COVID-19 vaccines. To be registered for use, these vaccines must have met the TGA's high standards for quality, safety and effectiveness. Four main COVID-19 vaccines are currently in use in Australia - Comirnaty (Pfizer), Spikevax (Moderna), Vaxzevria (AstraZeneca), and Nuvaxovid (Novavax).
0 Comments
Leave a Reply. |